NCT07900256
A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Complete Response Rate (CRR)
Timeframe: Up to 6 months after treatment initiation
Duration of Complete Response (DOR)
Timeframe: From the date of first documented CR until disease recurrence, progression, or the last follow-up, up to 36 months.
Secondary (5)
Pregnancy Rate
Live Birth Rate
Recurrence Rate
Incidence of Adverse Events
Changes in Serum Tumor Markers
Arms and interventions
Cadonilimab Combined With Megestrol AcetateExperimental
Participants will receive cadonilimab 6 mg/kg intravenously every 3 weeks in combination with oral megestrol acetate 160 mg once daily. Treatment response will be assessed approximately every 12 weeks for up to 6 months. Participants who achieve two consecutive pathological complete responses will discontinue both treatments and receive a levonorgestrel-releasing intrauterine system for maintenance management.
Drugs: Cadonilimab, Megestrol Acetate (MA)
Combination products: Levonorgestrel-releasing intrauterine system